SCHEMBL4367378

SCHEMBL4367378

CCCOc1ccc([C](c2ccccc2)c2ccc(OCCC)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.55
MEN1 O00255 1/20 0.55
POLB P06746 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.54
PLK1 P53350 1/20 0.54
MAPT P10636 3/20 0.54
RAB9A P51151 2/20 0.54
NPC1 O15118 1/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
LTA4H P09960 3/20 0.53
PKM P14618 1/20 0.52
GAA P10253 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP19A1 P11511 1/20 0.51
LMNA P02545 1/20 0.50
MAPK1 P28482 1/20 0.50
TP53 P04637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4362617 1.00 KMT2A (0.55) KMT2AMEN1POLBL3MBTL1PLK1
SCHEMBL4365542 0.92 LTA4H (0.63) KMT2AMEN1RAB9ANPC1LTA4H
SCHEMBL4366629 0.92 LTA4H (0.63) KMT2AMEN1RAB9ANPC1LTA4H
SCHEMBL5820211 0.87 TP53 (0.68) PLK1MAPTRAB9ANPC1LTA4H
SCHEMBL382628 0.87 TP53 (0.68) PLK1MAPTRAB9ANPC1LTA4H
SCHEMBL4798961 0.87 TP53 (0.68) PLK1MAPTRAB9ANPC1LTA4H
SCHEMBL4801986 0.87 TP53 (0.68) PLK1MAPTRAB9ANPC1LTA4H
SCHEMBL382171 0.87 TP53 (0.68) PLK1MAPTRAB9ANPC1LTA4H
SCHEMBL5814527 0.87 TP53 (0.68) PLK1MAPTRAB9ANPC1LTA4H
SCHEMBL5819932 0.87 TP53 (0.68) PLK1MAPTRAB9ANPC1LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2749566-B1 SOLID-PHASE CARRIER FOR AMINATED OLIGONUCLEOTIDE AIST (JP) 2018-05-09 EP disclosed
US-9428809-B2 Solid-phase carrier for aminated oligonucleotide NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2016-08-30 US disclosed
US-20140187724-A1 SOLID-PHASE CARRIER FOR AMINATED OLIGONUCLEOTIDE NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2014-07-03 US disclosed
EP-2749566-A1 SOLID-PHASE CARRIER FOR AMINATED OLIGONUCLEOTIDE National Institute of Advanced Industrial Science And Technology (JP) 2014-07-02 EP disclosed
EP-1908829-B1 OLIGONUCLEOTIDE PROBE NAT INST OF ADVANCED IND SCIEN (JP) 2014-01-08 EP disclosed
US-7491857-B2 Oligonucleotide probe NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2009-02-17 US disclosed
US-20080227968-A1 Oligonucleotide Probe NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2008-09-18 US disclosed
EP-1908829-A1 OLIGONUCLEOTIDE PROBE National Institute of Advanced Industrial Science and Technology (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227968-A1 Oligonucleotide Probe APEX1, RNGTT, RNASEH1 KMT2A 3173/4885MEN1 1946/4885POLB 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.